From DCAT Value Chain Insights (VCI)
Sarepta Therapeutics, a Cambridge, Massachusetts-headquartered biopharmaceutical company, has been informed that Edward Kaye, MD, president and chief executive officer (CEO), will resign from his position upon the conclusion of his current employment term on September 20, 2017 or some other future date, according to a Sarepta company filing with the US Securities and Exchange Commission (SEC). Dr. Kaye will continue to serve as a director following his resignation.
In addition to Dr. Kaye’s resignation, Jean-Paul Kress, MD, a director of the company, has informed the board that he has elected to not stand for re-election in anticipation of time commitments and a possible conflict of interest associated with his future endeavors. Dr. Kress will complete his term on the board at the conclusion of the company’s 2017 annual stockholders meeting. Dr. Kress’s decision to not stand for re-election was not because of a disagreement with the company on any matter relating to the company’s operations, policies, or practices, according to Sarepta in its SEC filing.
Source: Sarepta Therapeutics filing with the US Securities and Exchange Commission
Thank you for reading DCAT Value Chain Insights (VCI), an information resource from the
Drug, Chemical & Associated Technologies Association (DCAT).
Learn more and sign up to receive a complimentary subscription